Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess
Our study identified and compared potential and novel ADRs between EV and Erdafitinib, providing key insights into their safety profiles and highlighting the need for personalized treatment strategies based on individual patient risk factors.
Authors
- Chen‐Yang Shen (ORCID: https://orcid.org/0000-0001-5555-9950)
- Meiqi Xu (ORCID: https://orcid.org/0000-0001-9481-239X)
- Qian Guo (ORCID: https://orcid.org/0000-0002-1211-6436)
- Xiancheng Li (ORCID: https://orcid.org/0000-0001-8547-8609)
- Zhiqi Chen (ORCID: https://orcid.org/0000-0003-1981-1164)
- Yuanbin Huang
- Fei Liu (ORCID: https://orcid.org/0000-0002-9963-9810)
- Xiuli Ma (ORCID: https://orcid.org/0000-0003-3051-5075)
- Jiawen Wang (ORCID: https://orcid.org/0009-0005-2775-1845)
- Wei Wang (ORCID: https://orcid.org/0000-0003-1568-222X)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- Fujian Provincial Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-12-06
- DOI
- https://doi.org/10.3389/fphar.2024.1503154
- Citations
- 7
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 3.13